Veronica Francardo

Dr. Veronica Francardo

Auris Medical

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in Progress in Neurobiology
Verified
Journal Article
Closed access
MBMatthieu F. Bastide
Matthieu F. Bastide
WMWassilios Meissner
Wassilios Meissner
Barbara PicconiBarbara Picconi
Barbara Picconi
SFStefania Fasano
Stefania Fasano
Pierre-Olivier FernagutPierre-Olivier Fernagut
Pierre-Olivier Fernagut
Erwan BezardErwan Bezard
Erwan Bezard

1 November 2015 in Neuron
Verified
Journal Article
Closed access
WSWeixing Shen
Weixing Shen
JPJoshua L. Plotkin
Joshua L. Plotkin
Veronica FrancardoVeronica Francardo
Veronica Francardo
WKWai Kin D. Ko
Wai Kin D. Ko
ZXZhong Xie
Zhong Xie
D. James SurmeierD. James Surmeier
D. James Surmeier

22 April 2014 in Brain
Verified
Journal Article
Closed access
PDF file
Veronica FrancardoVeronica Francardo
Veronica Francardo
FBFrancesco Bez
Francesco Bez
TWTadeusz Wieloch
Tadeusz Wieloch
HNHans Nissbrandt
Hans Nissbrandt
KRKarsten Ruscher
Karsten Ruscher
ACAngela M Cenci
Angela M Cenci
The sigma-1 receptor, an endoplasmic reticulum-associated molecular chaperone, is attracting great interest as a potential target for neuroprotective treatments. We provide the first evidence that pharmacological modulation of this protein produces functional neurorestoration in experimental parkinsonism. Mice with intrastriatal 6-hydroxydopamine lesions were treated daily with the selective sigma-1 receptor agonist, PRE-084, for 5 weeks. At the dose of 0.3 mg/kg/day, PRE-084 produced a gradual and significant improvement of spontaneous forelimb use. The behavioural recovery was paralleled by an increased density of dopaminergic fibres in the most denervated striatal regions, by a modest recovery of dopamine levels, and by an upregulation of neurotrophic factors (BDNF and GDNF) and their downstream effector pathways (extracellular signal regulated kinases 1/2 and Akt). No treatment-induced behavioural-histological restoration occurred in sigma-1 receptor knockout mice subjected to 6-hydroxydopamine lesions and treated with PRE-084. Immunoreactivity for the sigma-1 receptor protein was evident in both astrocytes and neurons in the substantia nigra and the striatum, and its intracellular distribution was modulated by PRE-084 (the treatment resulted in a wider intracellular distribution of the protein). Our results suggest that sigma-1 receptor regulates endogenous defence and plasticity mechanisms in experimental parkinsonism. Boosting the activity of this protein may have disease-modifying effects in Parkinson’s disease. * Abbreviations : ERK1/2 : extracellular signal-regulated kinases PRE-084 : 2-morpholin-4-ylethyl 1-phenylcyclohexane-1-carboxylate Sig-1R : sigma-1 receptor

1 June 2011 in Neurobiology of Disease
Verified
Journal Article
Closed access
Veronica FrancardoVeronica Francardo
Veronica Francardo
ARAlessandra Recchia
Alessandra Recchia
NPNataljia Popovic
Nataljia Popovic
DADaniel Andersson
Daniel Andersson
HNHans Nissbrandt
Hans Nissbrandt
ACAngela M Cenci
Angela M Cenci

29 November 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
SFStefania Fasano
Stefania Fasano
Erwan BezardErwan Bezard
Erwan Bezard
ADAngela D'Antoni
Angela D'Antoni
Veronica FrancardoVeronica Francardo
Veronica Francardo
MIMarzia Indrigo
Marzia Indrigo
RBRiccardo Brambilla
Riccardo Brambilla
L -dopa–induced dyskinesia (LID) is a common debilitating complication of dopamine replacement therapy in Parkinson's disease. Recent evidence suggests that LID may be linked causally to a hyperactivation of the Ras–ERK signaling cascade in the basal ganglia. We set out to determine whether specific targeting of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1), a brain-specific activator of the Ras–ERK pathway, may provide a therapy for LID. On the rodent abnormal involuntary movements scale, Ras-GRF1–deficient mice were significantly resistant to the development of dyskinesia during chronic l -dopa treatment. Furthermore, in a nonhuman primate model of LID, lentiviral vectors expressing dominant negative forms of Ras-GRF1 caused a dramatic reversion of dyskinesia severity leaving intact the therapeutic effect of l -dopa. These data reveal the central role of Ras-GRF1 in governing striatal adaptations to dopamine replacement therapy and validate a viable treatment for LID based on intracellular signaling modulation.

24 November 2015 in Neurology
Verified
Journal Article
Open access
PDF file
SJShorena Janelidze
Shorena Janelidze
DLDaniel Lindqvist
Daniel Lindqvist
Veronica FrancardoVeronica Francardo
Veronica Francardo
SHSara Hall
Sara Hall
HZHenrik Zetterberg
Henrik Zetterberg
OHOskar Hansson
Oskar Hansson
Objective: To study biomarkers of angiogenesis in Parkinson disease (PD), and how these are associated with clinical characteristics, blood–brain barrier (BBB) permeability, and cerebrovascular disease. Methods: In this cross-sectional analysis, 38 elderly controls and 100 patients with PD (82 without dementia and 18 with dementia) were included from the prospective Swedish BioFinder study. CSF samples were analyzed for the angiogenesis biomarkers vascular endothelial growth factor (VEGF); its receptors, VEGFR-1 and VEGFR-2; placental growth factor (PlGF); angiopoietin 2 (Ang2); and interleukin-8. BBB permeability, white matter lesions (WMLs), and cerebral microbleeds (CMB) were assessed. CSF angiogenesis biomarkers were also measured in 2 validation cohorts: (1) 64 controls and 87 patients with PD with dementia; and (2) 35 controls and 93 patients with neuropathologically confirmed diagnosis of PD with and without dementia. Results: Patients with PD without dementia displayed higher CSF levels of VEGF, PlGF, and sVEGFR-2, and lower levels of Ang2, compared to controls. Similar alterations in VEGF, PlGF, and Ang2 levels were observed in patients with PD with dementia. Angiogenesis markers were associated with gait difficulties and orthostatic hypotension as well as with more pronounced BBB permeability, WMLs, and CMB. Moreover, higher levels of VEGF and PlGF levels were associated with increased CSF levels of neurofilament light (a marker of neurodegeneration) and monocyte chemotactic protein–1 (a marker of glial activation). The main results were validated in the 2 additional cohorts. Conclusions: CSF biomarkers of angiogenesis are increased in PD, and they are associated with gait difficulties, BBB dysfunction, WMLs, and CMB. Abnormal angiogenesis may be important in PD pathogenesis and contribute to dopa-resistant symptoms.